Grail raises $390M for multicancer liquid biopsy

By LabPulse.com staff writers

May 7, 2020 -- Menlo Park, CA-based startup Grail has raised an additional $390 million to advance its multicancer blood test, which is being validated for the early detection of 50 different tumor types.

Grail said the new cash infusion came in a series D round that included existing investors such as Illumina, as well as new backers including the Public Sector Pension Investment Board, the Canada Pension Plan Investment Board, and two undisclosed investors.

In addition to Illumina, Grail's investors have included Amazon, Bill Gates, Bezos Expeditions, Bristol-Myers Squibb, and Celgene. The company has raised a total of $1.9 billion since 2016.

Industry roundup: Oncology dominates noncoronavirus IVD news
There's no doubt that COVID-19 tests remain a focal point for IVD research and development. But companies increasingly are announcing new non-COVID-19...
Thrive blood test, PET/CT a winning combination in multicancer screening
An investigational blood test paired with positron emission tomography/computed tomography (PET/CT) imaging showed potential for increasing the yield...
Grail kicks off real-world study of multicancer blood test
Grail announced that a prospective interventional study is underway to evaluate its multicancer blood test for guiding patient management.
How Grail's blood test stacks up in gastrointestinal cancers
An investigational blood test developed by startup Grail has high sensitivity and specificity across a range of gastrointestinal cancer types, though...
Grail taps Bishop as new CEO as Cook steps down
Grail has appointed biotechnology veteran Hans Bishop as its new CEO, replacing Jennifer Cook, who is stepping down for family health reasons.

Copyright © 2020 LabPulse.com

Last Updated np 5/7/2020 4:43:36 PM